Skip to search formSkip to main contentSkip to account menu

zanolimumab

Known as: Anti-CD4 Monoclonal Antibody HuMax, HuMax-CD4 
A human IgG1k monoclonal antibody against the CD4 receptor on T-lymphocytes, with potential antineoplastic and immunosuppressing activities… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Comparison of different methods of thrombus permeability measurement and impact on recanalization in the INTERRSeCT multinational multicenter prospective cohort study
Purpose To compare the association of different measures of intracranial thrombus permeability on non-contrast computerized… 
2016
2016
BMS bets on targeting IL-8 to enhance cancer immunotherapies
VOLUME 34 NUMBER 10 OCTOBER 2016 NATURE BIOTECHNOLOGY “There’s good scientific evidence that the presence or absence of cells… 
2011
2011
Alemtuzumab‐resistant Sézary syndrome responding to zanolimumab *
Primary cutaneous T-cell lymphomas (CTCL) are rare malignancies characterized by clonal T-cell infiltrates (Kim et al, 2005… 
2007
2007
Zanolimumab (HuMax-CD4™), a Fully Human Monoclonal Antibody: Efficacy and Safety in Patients with Relapsed or Treatment-Refractory Non-Cutaneous CD4+ T-Cell Lymphoma.
Combination chemotherapy has been the basis of treatment for peripheral T-cell lymphoma (PTCL) for many years, but relapses are… 
2007
2007
A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity.
Zanolimumab is a human IgG1 antibody against CD4, which is in clinical development for the treatment of cutaneous and nodal T… 
Review
2007
Review
2007
A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.
Dermatologists use a variety of treatments for cutaneous T cell lymphoma (CTCL) or mycosis fungoides, in particular topical… 
2006
2006
Zanolimumab, a fully human monoclonal antibody: preliminary results of an ongoing clinical trial in CD4+ peripheral T-cell lymphomas (PTCL)
Zanolimumab (previously referred to as HuMax-CD4) is a fully human monoclonal IgG1k antibody. It is specific for the CD4 antigen… 
2004
2004
HuMax-CD4 may induce response in mycosis fungoides
  • 2004
  • Corpus ID: 195126590
2003
2003
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2003
2003
HuMax-CD4 for psoriasis: lack of significant results
  • 2003
  • Corpus ID: 195129987
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)